The China Cardiac Rhythm Management (CRM) Interventional landscape, Procedure and Technology Trends, Brand Perception, Competitive Intelligence and Future Outlook (2021-2026)

October 2022
The China Cardiac Rhythm Management (CRM) report is the first-ever syndicated report that covers the market landscape, procedural and technology trends, and competitive intelligence. The report is based on exhaustive secondary research and in-depth primary research conducted with performing physicians in Interventional Cardiology, Cardiac Electrophysiology departments, and Cardiac catheterization lab from level 2 and level 3 hospitals in China.

The report covers:

  • Cardiac implantable electrical device (CIED) procedures: implant procedures for Cardiac Arrhythmia.
  • Interventional devices: implantable pacemakers, implantable defibrillators (ICDs), and cardiac resynchronization therapy (CRTs) devices
  • Procedure trends: stages of the disease, route of access used for the intervention, and type pf interventions.


  • Insights on hospital structure and utilization, physician treatment selection criteria, current and upcoming policies for diagnosis and treatment, and payer coverage are delved upon.
  • Physicians’ brand perception and their rank of medical device companies based on 15 KPIs such as technology, clinical evidence, patient outcome, etc. Moreover, diligent examination of physician’s brand usage and brand satisfaction levels, and the factors such as ease of use of the device, and cost-effectiveness among others effecting brand usage have been covered.
  • Future trends such as such as the continued rise in adoption of leadless pacemakers, miniaturization of devices, increased battery longevity, and reducing complications of implanted devices are covered in the report. Expanding indications for cardiac device implants with the rise in the elderly population is expected to drive growth in the CRM market in China. Implementation of policies that encourage local manufacturing is expected to support Chinese companies to gain market share by 2030. In China’s 14th Five-Year Plan, the new economic model of “dual-circulation” in trade and centralized state procurement policy known as volume-based procurement (VBP) was launched in 2019 and is expected to lower the cost of high-end medical devices.
  • Competitor landscape covers market events such as emerging companies, product approvals, clinical trials, partnerships etc. Competitor activities such as NMPA approval of Platinium ICD from MicroPort CRM are covered in the report.

What’s in it for you?

  • This report will help cardiac implantable electrical device (CIED) companies understand the cardiac arrhythmic intervention landscape, procedural and technology trends, the brand perception, in China.
  • The report is a great resource to plan your market strategy to capitalize on upcoming trends and potential disruptors in the cardiac implantable electrical device (CIED) market.
The deliverable includes a 100+ slide MS PowerPoint report and an MS Excel-based 5-Year market forecast model.
Contact us below for further details regarding the exclusive data and insights in the report or for an exploratory analyst walkthrough of the report.

    Drop Us A Line

    We provide the best insights for your business